
CRL Earnings
Charles River Laboratories International Inc
- Overview
- Forecast
- Valuation
- Earnings
Earning Analysis
Welcome to our in-depth analysis of Charles River Laboratories International Inc(CRL) earnings, offering investors a detailed look into the company’s financial performance, revenue trends, earnings per share (EPS), and market reactions. This page provides a comprehensive overview of Charles River Laboratories International Inc earnings history, forecasts, and key financial metrics, empowering you with the data needed to make informed investment decisions. Whether you're tracking quarterly results, analyzing earnings surprises, or exploring future projections, our detailed breakdown covers it all.
Earnings Forecast
Revenue
EPS
Currency: USD
Actual
Estimate
Surprise Analysis
FY2025Q2 | 2025-08-06 | Pre-Market | 2.50 | 3.12 | +24.80 | 989.58M | 1.03B | +4.30 | -10.25 | -11.08 |
FY2025Q1 | 2025-05-07 | Pre-Market | 2.06 | 2.34 | +13.59 | 941.94M | 984.17M | +4.48 | +18.68 | +23.98 |
FY2024Q4 | 2025-02-19 | Pre-Market | 2.50 | 2.66 | +6.40 | 983.63M | 1.00B | +1.92 | +6.87 | +8.23 |
FY2024Q2 | 2024-08-07 | Pre-Market | 2.39 | 2.80 | +17.15 | 1.02B | 1.03B | +0.18 | -12.60 | -11.06 |
FY2024Q1 | 2024-05-09 | - | 2.05 | 2.27 | +10.73 | 993.46M | 1.01B | +1.82 | -2.21 | -1.16 |
FY2023Q4 | 2024-02-14 | - | 2.39 | 2.46 | +2.93 | 991.25M | 1.01B | +2.24 | +11.30 | +9.47 |
FY2023Q3 | 2023-11-08 | - | 2.35 | 2.72 | +15.74 | 1.00B | 1.03B | +2.61 | -3.74 | -2.43 |
FY2023Q2 | 2023-08-09 | - | 2.63 | 2.69 | +2.28 | 1.05B | 1.06B | +0.59 | +4.64 | +1.86 |
- | 2023-05-11 | - | 2.59 | 2.78 | +7.34 | - | - | - | +5.07 | +5.63 |
- | 2023-02-22 | - | 2.75 | 2.98 | +8.36 | - | - | - | -10.06 | -9.96 |
CRL Earnings Analysis
Our earnings analysis provides a granular look at the company’s performance across recent fiscal quarters, highlighting key metrics such as revenue, EPS, and operating margins. By examining actual results against analyst estimates, we uncover trends and surprises that drive stock price movements, offering valuable insights for both short-term traders and long-term investors.
In the most recent quarter, Charles River Laboratories International Inc reported performance for FY2025Q2, announced on 2025-08-06. The company achieved an EPS of 3.12, compared to analyst estimates of 2.50 by 24.80% . Revenue for the quarter reached 1.03B compared to expectations of 989.58M by 4.30% .
The stock price reacted with a -10.25% one-day change and a -11.08% five-day change following the earnings release. These movements reflect market reaction in Charles River Laboratories International Inc growth trajectory and strategic initiatives.
CRL Earnings Forecast
Looking ahead, Charles River Laboratories International Inc(CRL) remains a focal point for investors seeking growth opportunities. Analyst forecasts for 2025/Q3 project quarter revenue of 980.74M and an EPS of 2.36.
However, recent estimate revisions provide additional context. Over the past three months, revenue estimates for FY2025 have been Revise Upward by 0.36%, while EPS estimates have been Revise Upward by 0.26%. For the upcoming Q3 2025, revenue estimates have been adjusted Revise Upward by 2% . These revisions correlate with a 11.55% change in stock price over the same period, suggesting potential buying opportunities for investors who believe in Charles River Laboratories International Inc long-term fundamentals.
The relationship between earnings forecast revisions and stock price movements is critical for investors. Positive revisions in revenue or EPS often signal strengthening fundamentals, making temporary price dips attractive entry points. Conversely, downward revisions may reflect short-term challenges.
Estimate Revision
The chart shows the correlation between CRL's stock price and earnings forecast revisions. Positive revisions in Revenue or EPS often strengthen the stock's fundamentals, making price dips potential buying opportunities.
Revenue Estimates for FY2025
Revise Upward

+0.36%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward

+0.26%
In Past 3 Month
Revenue Estimates for Q3 2025
Revise Upward

+2%
In Past 3 Month
Stock Price
Go Up

+11.55%
In Past 3 Month
1Y
3Y
5Y
Annual FY 2025
Currency: USD
1Y
3Y
5Y
--
Revenue Estimate-Annual FY 2025:3.90B
--
EPS Estimate-Annual FY 2025:9.63
—
Stock Price155.00
CRL Revenue and EPS Performance: A Historical Perspective
Charles River Laboratories International Inc revenue and earnings per share (EPS) performance over recent quarters provides a clear picture of its financial health. Below is a detailed breakdown of the company’s earnings history, showcasing actual results, analyst estimates, and surprise percentages for key fiscal quarters:
FY2025Q2 (2025-08-06,Pre-Market):
EPS: 3.12 (Actual) vs.2.50 (Estimate) (24.80%)
Revenue: 1.03B (Actual) vs. 989.58M (Estimate) (4.30%)
Price Reaction: -10.25%(1-Day), -11.08%(5-Day)
FY2025Q1 (2025-05-07,Pre-Market):
EPS: 2.34 (Actual) vs.2.06 (Estimate) (13.59%)
Revenue: 984.17M (Actual) vs. 941.94M (Estimate) (4.48%)
Price Reaction: 18.68%(1-Day), 23.98%(5-Day)
FY2024Q4 (2025-02-19,Pre-Market):
EPS: 2.66 (Actual) vs.2.50 (Estimate) (6.40%)
Revenue: 1.00B (Actual) vs. 983.63M (Estimate) (1.92%)
Price Reaction: 6.87%(1-Day), 8.23%(5-Day)
Earnings Reaction
The chart below shows how CRL performed 10 days before and after its earnings report, based on data from the past quarters. Typically, CRL sees a -0.54% change in stock price 10 days leading up to the earnings, and a +0.75% change 10 days following the report. On the earnings day itself, the stock moves by +0.77%. This data can give you a slight idea of what to expect for the next quarter's release.
For example, in JUN/2025, the stock changed -0.37% on the day following the earnings release and then changed by 3.11% over the next 10 days. These patterns provide investors with valuable insights into potential price movements and help inform trading strategies around earnings events.
Transcript Summary
Charles River Laboratories International Inc (CRL) Q2 2025 Earnings Call Summary
Negative
2025-08-06
The earnings call summary indicates declining revenue and operating margins, with mixed demand in biotech and a significant headwind from the loss of a CDMO client. Despite raised EPS guidance and stable DSA pricing, the outlook includes increased hiring costs and margin pressures. The Q&A section highlights concerns over client cancellations, hiring impacts, and CDMO performance. The negative revenue guidance and declining margins outweigh the positive EPS and free cash flow guidance, leading to an overall negative sentiment.
Charles River Laboratories International Inc (CRL) Q1 2025 Earnings Call Summary
Neutral
2025-05-07
The earnings call presents mixed signals: a decline in revenue and organic revenue, but an improvement in operating margin and EPS. The share repurchase program is a positive factor, yet concerns about FDA guidance and uncertain long-term growth due to regulatory changes temper enthusiasm. The Q&A revealed unclear responses from management, particularly on FDA impact, which adds uncertainty. Despite the positive cash flow and reduced capital expenditures, the lack of clarity on future growth and FDA impacts leads to a neutral sentiment.
Charles River Laboratories International Inc (CRL) Q4 2024 Earnings Call Summary
Negative
2025-03-13
The earnings call reveals several challenges: a significant revenue and EBITDA decline, geopolitical tensions, and supply chain issues. Despite some positive trends, like improved order intake and optimistic guidance for North America, the overall sentiment is negative due to the poor financial performance, especially in EMEA, and unclear management responses. The restructuring and cost-saving measures are overshadowed by ongoing market volatility and material cost concerns. The dividend distribution is a minor positive, but not enough to offset the negative factors.
Charles River Laboratories International Inc (CRL) Q4 2024 Earnings Call Summary
Neutral
2025-02-20
The earnings call summary presents a mixed outlook. While the company reported better-than-expected Q4 performance and raised EPS guidance, early-stage spending constraints and competitive pressures pose risks. The share repurchase program is a positive, but stable demand KPIs and cautious client activities suggest limited growth. The Q&A section did not reveal significant new insights, and management's cautious tone on future demand and restructuring impacts suggests a neutral sentiment. Overall, the stock price is likely to remain stable over the next two weeks.
Charles River Laboratories International, Inc. (CRL) Q3 2024 Earnings Call Summary
Neutral
2024-11-06
The earnings call reveals mixed signals: strong cost-saving initiatives and a $1 billion stock repurchase are positive, but revenue and EPS guidance are weak, with anticipated margin pressure. The Q&A highlights management's cautious optimism but also concerns about pricing headwinds and uncertain future demand. Despite some positive elements, the overall sentiment is tempered by uncertainties, leading to a neutral outlook for stock price movement in the short term.
Charles River Laboratories International Inc (CRL) Q2 2024 Earnings Call Summary
Neutral
2024-08-07
The earnings call summary indicates mixed signals: a decline in revenue but an increase in EPS and operating margins. The new $1 billion stock repurchase is positive, but concerns about declining demand, particularly in global biopharma, and unclear management responses temper optimism. The reaffirmed revenue growth guidance and restructuring cost savings provide stability, but potential headwinds in demand recovery and pricing pressure in DSA suggest a neutral sentiment. The market reaction over the next two weeks is expected to be within a neutral range (-2% to 2%).
People Also Watch

CHE
Chemed Corp
450.360
USD
+1.63%

RH
RH
245.680
USD
+3.54%

MKTX
Marketaxess Holdings Inc
189.000
USD
+0.41%

SARO
StandardAero, Inc.
28.160
USD
-1.78%

LTM
LATAM Airlines Group SA
44.750
USD
+3.35%

HLNE
Hamilton Lane Inc
160.880
USD
+1.39%

KT
KT Corp
20.270
USD
+0.85%

FSV
FirstService Corp
199.830
USD
+2.38%

PAC
Grupo Aeroportuario del Pacifico SAB de CV
244.700
USD
-2.16%

FLS
Flowserve Corp
53.970
USD
+1.49%
FAQ

What were the key highlights of CRL’s latest earnings report for FY2025Q2?
CRL reported its FY2025Q2 earnings on 2025-08-06, showcasing a revenue of 1.03B against an estimate of 989.58M, resulting in a 4.3% surprise. The EPS was 3.12, surpassing the expected 2.5 by 24.8% . The stock experienced a -10.25% price change on the earnings day and a -11.08% change over the next five days, reflecting market reactions to the results.

How did CRL’s stock price react after the FY2025Q2 earnings release?

What are the revenue and EPS estimates for CRL for 2025/Q3?

How does CRL’s stock price correlate with earnings forecast revisions?

What should investors expect from CRL’s next earnings report?
